IRX5 and hepatocellular carcinoma: IRX5 activity is also present in the stromal and proliferative late blastemal/early epithelial cells in developing kidneys and Wilms tumours.16 Myrthue et al had revealed that knockdown of IRX5 by RNA interference significantly reduction in LNCaP cell viability, which resulted in increased LNCaP cell apoptosis and was partially mediated by p53.17 However, the role of IRX5 in HCC is unknown.